R&D News | pharmaphorum

News

Gilead plans European trial of twice-yearly HIV PrEP drug

Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

News

Nucleus RadioPharma raises $56m in first round financing

There’s a new kid on the block in the fast-growing radiopharmaceuticals category, as Nucleus RadioPharma chalks up an oversubscribed Series A that raised $56 million that

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

News

Owkin signs up another pharma partner for its AI platform

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US

News

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts

Gilead plans European trial of twice-yearly HIV PrEP drug

Roche sticks with molecular glue, partnering Monte Rosa

Nucleus RadioPharma raises $56m in first round financing

Roche builds gene therapy portfolio with SpliceBio deal

Owkin signs up another pharma partner for its AI platform

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks